Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Amgen
Hoffmann-La Roche
Lumos Pharma
Actuate Therapeutics Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Eisai Inc.
Vividion Therapeutics, Inc.
Centre Oscar Lambret
QuantumLeap Healthcare Collaborative
Hoffmann-La Roche
Hoffmann-La Roche
Inhibrx Biosciences, Inc
AbbVie
Università Vita-Salute San Raffaele
UNICANCER
University of Kentucky
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
National University Hospital, Singapore
Nurix Therapeutics, Inc.
Tesaro, Inc.
AbbVie
ALX Oncology Inc.
Merck Sharp & Dohme LLC
Sun Yat-sen University
DEKA Biosciences
Mario Negri Institute for Pharmacological Research
Shandong Cancer Hospital and Institute
Ohio State University Comprehensive Cancer Center
Bristol-Myers Squibb
GlaxoSmithKline
Jazz Pharmaceuticals
Eli Lilly and Company
iTeos Therapeutics
Taiho Oncology, Inc.
GlaxoSmithKline
University of California, San Diego
The First Affiliated Hospital of Guangzhou Medical University
Kyowa Kirin Co., Ltd.
Zhongnan Hospital
Hoffmann-La Roche
Puma Biotechnology, Inc.
Fondazione Michelangelo
Loyola University
AbbVie
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.